TY - JOUR T1 - Utilization of wearable activity monitors to support physical activity interventions in neurodegenerative diseases: a feasibility study JF - medRxiv DO - 10.1101/2022.05.31.22275824 SP - 2022.05.31.22275824 AU - Hai-Jung Steffi Shih AU - Lori Quinn AU - Philippa Morgan-Jones AU - Katrina Long AU - Abigail R. Schreier AU - Ciaran P. Friel Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/05/31/2022.05.31.22275824.abstract N2 - Purpose To evaluate the feasibility of using wearable activity monitors as part of a physical activity (PA) intervention and describe patterns of device weartime and PA behavior in people with Parkinson (PD) and Huntington disease (HD).Materials and Methods Secondary analyses were conducted on two pilot studies where people with early-stage PD (n=13) and HD (n=14) enrolled in a 4-month PA coaching program. Participants wore a Fitbit Charge 2 and physical and occupational therapists guided them through understanding of PA data and goal-setting to build autonomy and facilitate PA uptake. Wear time, wear habits (delineated based on nighttime wear), and activity metrics including steps, resting heart rate, and metabolic equivalent of task (MET) *minutes were analyzed.Results Retention rate of the intervention was 85%. Participants had a mean (SD) of 92.3(9.2)% valid wear days over the intervention period. Average daily wear time was 18.4(4.5) hours, with an initial 2-week period of high wear time fluctuation. Regardless of diagnosis, day & night Fitbit wearers had more improvements in steps (d=1.02) and MET*min/week (d=0.69) compared to day-only wearers.Conclusions Implementing wearable activity monitors in a PA coaching intervention was feasible and provided insight into longitudinal PA behavior in people with neurodegenerative diseases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03696589 NCT03306888Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Teachers College, Columbia University and the New York State Psychiatric Institute gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -